<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388920</url>
  </required_header>
  <id_info>
    <org_study_id>TH9507-CTR-1025</org_study_id>
    <nct_id>NCT01388920</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theratechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theratechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A significant proportion of COPD subjects experience muscle wasting, which has been
      associated with increased morbidity, impaired physical functioning, and a poor quality of
      life.

      Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular,
      weakness of peripheral muscles has been reported to play an important role in the reduced
      functional capacity and impaired exercise performance.

      The primary objective of this study is to investigate the effect of tesamorelin, in
      conjunction with exercise training, on lean body mass measured by dual energy x-ray
      absorptiometry (DXA) scan.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated based on a non-safety related corporate decision.
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Lean Body Mass at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Exercise Capacity at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peripheral Muscle Strength at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-reported Outcomes at 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number and percentage of subjects with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbations</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency and severity of COPD exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline in fasting blood glucose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Tesamorelin 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesamorelin 2 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tesamorelin 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesamorelin 3 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesamorelin</intervention_name>
    <arm_group_label>Tesamorelin 2 mg</arm_group_label>
    <arm_group_label>Tesamorelin 3 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 40-75 years (y) inclusive

          -  Documented diagnosis of moderate to very severe COPD (GOLD stage 2, 3, or 4)

          -  Stable COPD (i.e., no exacerbation) for at least 6 weeks prior to screening

          -  Able to participate in a supervised exercise training program

          -  Evidence of muscle wasting

        Exclusion Criteria

          -  Participation in a pulmonary rehabilitation program or in any supervised exercise
             program during the 4 months prior to screening

          -  More than 4 exacerbations in the year prior to screening

          -  Life-threatening exacerbation in the year prior to screening

          -  Requirement for long-term oxygen therapy (&gt; 12 hours of oxygen per day)

          -  Critical illness or co-morbid conditions that may interfere with study conduct or
             endpoint measurements

          -  Use of agents known to increase lean body mass within 3 months prior to screening

          -  Hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head
             trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Casaburi, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2011</study_first_posted>
  <results_first_submitted>April 4, 2014</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Muscle wasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tesamorelin 2 mg</title>
          <description>Tesamorelin 2 mg/day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Tesamorelin 3 mg</title>
          <description>Tesamorelin 3 mg/day for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo for 6 monts</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tesamorelin 2 mg</title>
          <description>Tesamorelin 2 mg/day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Tesamorelin 3 mg</title>
          <description>Tesamorelin 3 mg/day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo for 6 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="0"/>
                    <measurement group_id="B2" value="51" spread="0"/>
                    <measurement group_id="B4" value="55" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Lean Body Mass at 6 Months</title>
        <description>The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan</description>
        <time_frame>6 months</time_frame>
        <population>The primary objective of the study was the change in lean body mass between baseline and Month 6. However, the study was halted approximately 1 month after patient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tesamorelin 2 mg</title>
            <description>Tesamorelin 2 mg/day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Tesamorelin 3 mg</title>
            <description>Tesamorelin 3 mg/day for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lean Body Mass at 6 Months</title>
          <description>The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan</description>
          <population>The primary objective of the study was the change in lean body mass between baseline and Month 6. However, the study was halted approximately 1 month after patient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Exercise Capacity at 6 Months</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peripheral Muscle Strength at 6 Months</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-reported Outcomes at 6 Months</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number and percentage of subjects with adverse events</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbations</title>
        <description>Frequency and severity of COPD exacerbations</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose</title>
        <description>Changes from baseline in fasting blood glucose</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tesamorelin 2 mg</title>
          <description>Tesamorelin 2 mg/day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Tesamorelin 3 mg</title>
          <description>Tesamorelin 3 mg/day for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Medical Advisor</name_or_title>
      <organization>Theratechnologies</organization>
      <phone>514-336-7800</phone>
      <email>jmamputu@theratech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

